Young Kwang Chae
co-director and Assistant Professor
Northwestern University
USA
Biography
Dr. Young Chae is a clinical trialist and a physician-scientist dedicated to translational research that enables personalized medicine in cancer patients. In addition to his clinical training as internist, hematologist, and medical oncologist, he is trained in molecular biology, genomics, epigenomics, proteomics and biostatistics. He considers himself as a bridge between lab and clinic who brings clinical insights into the benchside and also takes major scientific breakthroughs into the bedside. Currently, he is the co-director of the developmental therapeutics program of the division of hematology oncology and the co-chair of the early phase multi-histology disease team at the Lurie Comprehensive Cancer Center of Northwestern University. He has maintained his focus in early phase clinical trials throughout his career. He is in charge of many targeted therapy clinical trials and immunotherapy combination trials applying tissue and blood based biomarkers including comprehensive genomic profiling via next generation sequencing. His interest is in thoracic oncology, precision oncology, novel combination therapies including immunotherapies and targeted therapies, rational clinical trial design and implementation of first in human clinical trials, and biomarker correlative studies that can help select patients predicted to have higher responses and lower toxicities to certain targeted therapies and immunotherapies. Above all, his passion is to help desperate patients including those with rare cancers who do not have standard of care treatment options or have become refractory to all existing treatment options with novel treatments through well designed clinical trials bringing the best science to patients. He is one of the current principal investors for the NCI MATCH trial and the SWOG DART trial.
Research Interest
His interest is in thoracic oncology, precision oncology, novel combination therapies including immunotherapies and targeted therapies, rational clinical trial design and implementation of first in human clinical trials, and biomarker correlative studies.